Advice
following a full submission:
caffeine citrate (Peyona®) is accepted for use within NHS Scotland.
Indication under review: treatment of primary apnoea of premature newborns.
In premature infants with apnoea of prematurity, caffeine citrate significantly reduced apnoeic episodes compared with placebo. A long-term placebo-controlled study demonstrated a reduced risk of disabilities relevant to these infants.
This SMC advice takes account of the benefits of a Patient Access Scheme (PAS) that improves the cost-effectiveness of caffeine citrate (Peyona®). This SMC advice is contingent upon the continuing availability of the PAS or an equivalent or lower list price in NHS Scotland.
Download detailed advice137KB (PDF)
Medicine details
- Medicine name:
- caffeine Citrate 20mg/ml solution for infusion and oral solution (Peyona)
- SMC ID:
- 814/12
- Indication:
- Treatment of primary apnoea of premature newborns.
- Pharmaceutical company
- Chiesi Limited
- BNF chapter
- Respiratory system
- Submission type
- Full
- Status
- Accepted
- Date advice published
- 09 September 2013